*Corresponding author:Li Xiao Rui, Department of Oncology, Xinxiang, Henan, China
Received: December 04, 2018; Published: December 13, 2018
To view the Full Article Peer-reviewed Article PDF
The morbidity of cutaneous melanoma has continued to increase in recent years. Patients with stage III disease are at higher risk for recurrence after locoregional resection and many will ultimately die from metastatic melanoma. BRAF inhibitors vemurafenib and dabrafenib have significantly improved progression-free survival (PFS) and overall survival (OS) as single agents compared with cytotoxic chemotherapy. Acquired resistance to BRAF inhibitors inevitably develops, resulting in a median progression-free survival of 6 to 8 months. Several clinical trials with combination treatment of dabrafenib(150 mg twice daily) plus trametinib(2 mg once daily) in stage III/Ⅳ BRAF-mutated melanoma have been reported. These clinical trials identify combination treatment of dabrafenib plus trametinib as front-line therapy in stage III/Ⅳ BRAF-mutated melanoma.
Keywords :Dabrafenib; Trametinib; Braf; Mek; Mutant; MelanomaMini Review| Result| Conclusion| References|